Identification of ACE2 mutations that modulate SARS-CoV-2 spike binding across multiple mammalian species

Authors
Pete Heinzelman¹ and Philip A. Romero¹,²*

¹Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA. ²Department of Chemical & Biological Engineering, University of Wisconsin-Madison, Madison, WI, USA.
*Correspondence: promero2@wisc.edu

Running Title
ACE2 mutations impact spike binding across multiple species

Keywords
Angiotensin Converting Enzyme II
Yeast surface display
Directed Evolution
Coronavirus
SARS-CoV-2
Covid-19
Mutation
Vaccine
Food Security
Mink

Abstract
Understanding how SARS-CoV-2 interacts with different mammalian angiotensin-converting enzyme II (ACE2) cell entry receptors will help elucidate determinants of intra- and cross-species virus transmission, facilitate development of effective new vaccines for both humans and livestock animals, and guide livestock farming and coronavirus screening procedures to ensure food supply security. In this work we applied laboratory directed evolution to several mammalian ACE2s with the goal of identifying conserved ACE2 mutations that increase spike binding affinity across multiple species. We found the Gln42Leu mutation increased ACE2-spike binding for human as well as four of four other mammalian ACE2s, while the Leu79Ile mutation had a similar effect for human and three of three mammalian ACE2 orthologs. These results are especially notable given the residues’ high levels of representation, i.e., 83% for Gln42 and 56% for Leu79, among annotated mammalian ACE2s. We also found that substitutions at ACE2 position 34, which is relatively variable across mammalian ACE2s, increased binding for multiple ACE2 orthologs. Taken together, these results speak strongly to the plausibility of SARS-CoV-2 strains with increased ability to cross species transmission barriers. Our results can guide further computational and experimental studies to develop biomedical technologies and animal husbandry practices that help protect both humans and livestock from existing and future SARS-CoV-2 variants.
**Introduction**

The SARS-CoV-2 coronavirus has demonstrated substantial ability to mutate in ways that increase its transmissibility among humans [1], reduce the effectiveness of COVID-19 vaccines [2], and enable bidirectional transmission of the virus between humans and animals [3]. These observations have motivated the development of novel COVID-19 vaccines and vaccine boosters for humans [4], vaccination agents for economically important animals [5], prospecting efforts centered on isolating viruses from wild animals to identify new coronavirus strains that possess potential to be transmitted to the human population [6], and establishment of livestock husbandry and coronavirus screening practices to reduce the likelihood of coronavirus infections spreading within farmed animal populations [7].

The above pursuits demand a deeper understanding of how sequence variation in both the ACE2 receptor and the viral spike protein influences transmission within the human population and across species barriers. In this work we explore how mutations in human and other mammalian ACE2s affect spike protein binding using a yeast surface display-based screening method [8]. We discovered that substitutions at ACE2 amino acid positions 34, 42, and 79 increased spike binding in several ACE2 orthologs. The increased binding of Gln42Leu and Leu79Ile mutations are especially noteworthy given that Gln appears at position 42 in 83% of annotated mammalian ACE2s, while Leu is present at position 79 in 56% of such proteins [9].

The above finding that ACE2 mutations have similar effects upon spike binding across multiple ACE2 orthologs suggests that mutations in the spike protein can also modulate the ACE2-spike binding interaction in a species-independent manner. It follows that mutant SARS-CoV-2, or other emergent coronaviruses, could feature spike proteins that impart cross-species transmission propensities greater than those for SARS-CoV-2 strains observed to date, thus motivating proactiveness and breadth of action with respect to vaccine development, novel coronavirus strain prospecting, and animal farming practices aimed at preventing and containing coronavirus infection. Combining our results with structural analysis of ACE2-spike binding interactions, comparisons of ACE2 sequences across mammalian species, and existing knowledge of SARS-CoV-2 mutations that increase spike binding *in vitro* [10] will provide a global view of viral emergence and transmission that will help mitigate the societal and economic impacts of current and future coronavirus outbreaks.

**Results**

Our work focused on four key mammalian ACE2 orthologs from *Homo sapiens*, *Felis catus* (domestic cat), *Canis familiarus* (domestic dog), and *Sus scrofa* (domestic pig). We cloned genes
encoding the peptidase domains (residues 19-614) of these four ACE2 orthologs into a yeast surface display vector (Supporting Figure 1) and measured their expression and spike binding using flow cytometry. As shown in Supporting Figure 2, all four of these ACE2s were well-displayed on the yeast surface and bound to recombinant SARS-2-CoV spike receptor binding domain (RBD) with the following rank order of flow cytometry assay binding signal values: human > cat ≈ pig > dog.

We performed random mutagenesis on the four ACE2 orthologs [11] and used three rounds of FACS-based enrichment to isolate high affinity mutants for each ortholog. We then performed flow cytometric analysis and DNA sequencing to confirm that we had isolated multiple unique high affinity clones from each library (Figure 1 & Supporting Table 1). The amino acid substitutions identified in the high affinity clones were distributed across the length of the protein sequence, but were concentrated in the N-terminal helices known to interact with the spike protein.

Figure 1. Flow cytometry dot plots for wild type and ACE2 random mutant library clones enriched after three rounds of FACS. X-axes denote Alexa488 fluorescence (ACE2 display). Y-axes denote Alexa647 fluorescence (ACE2 binding to spike protein). Plots depict dots for approximately $3 \times 10^4$ yeast cells. ACE2 yeast incubated with spike as follows: human - 1 nM, cat - 4 nM, pig - 4 nM, dog - 25 nM. For poorly understood biological reasons homogeneous populations of yeast carrying identical display plasmids feature 25% or greater cells (lower left of plots) that do not display protein.
We focused our further analysis on mutations that enhance spike binding and that also occur at highly conserved sites across annotated mammalian ACE2s [9]. The fact that mutations could enhance binding suggests these sites were originally suboptimal for binding and may be primed for the evolving virus to exploit. We identified positions 42 (83% percent representation for Gln) and 79 (56% representation for Leu) because they were present in our high affinity clones and are conserved across annotated mammalian ACE2s. Although ACE2s carrying mutations at position 34 were enriched in the cat, pig, and dog sorts this position is relatively variable, with His being most highly conserved at 34%, and thus not an ideal fit to the objective of assessing whether identical substitutions can increase spike binding affinity across multiple ACE2 orthologs.

We individually introduced the Gln42Leu and Leu79Ile mutations into each of the mammalian ACE2s and found both of these mutations substantially increased spike-binding signals (Figure 2). The Gln42Leu mutation increased the binding signal 10-400% across the four ACE2 orthologs, while Leu79Ile’s increases were in the 30-90% range.

![Figure 2. Dot plots for wild type ACE2 and Gln42Leu single mutants. X-axes denote Alexa488 fluorescence (ACE2 display). Y-axes denote Alexa647 fluorescence (binding to spike). Plots depict dots for approximately 3*10^4 yeast cells. ACE2 yeast incubated with spike as denoted in figure.](https://doi.org/10.1101/2021.03.16.435705)
Following on this result, we sought to further explore whether the Gln42Leu mutation would enhance spike binding in other mammalian ACE2s. We identified the ACE2 from the halcyon bat (*Rhinolophus alcyone*) as an additional ortholog that carries Gln at position 42, is compatible with our yeast display system, and binds to spike RBD (Supporting Figure 3). We found the Gln42Leu mutation also enhanced spike binding of the halcyon bat ACE2 (Supporting Figure 4). Finally, we tested the effect of the Gln42Leu in all five ACE2s across a wide range of RBD spike concentrations (Figure 3).

![SARS-CoV-2 RBD Spike Concentration](image)

**Figure 3.** Yeast display flow cytometry spike binding assay MFU values for wild type and Gln42Leu mutant ACE2s. MFU values are the mean of duplicate measurements. Error bars, shown for wild type and Gln42Leu mutant pig ACE2s, represent standard deviations. MFU values for yeast not incubated with spike are typically 30-50 MFU.

We examined the human ACE2-spike RBD co-crystal structure [12] to better understand how mutations at positions 34, 42, and 79 may enhance spike binding (Figure 4). We found Gln42’s side chain nitrogen atom is in contact with the backbone oxygen atom of spike RBD residue Gly446; a Gln to Leu substitution would be expected to eliminate this electrostatically unfavorable interaction. Regarding increased spike RBD binding signals for Leu79Ile mammalian ACE2 mutants, Leu79’s aliphatic sidechain is proximal to the phenyl ring of spike RBD residue Phe486.

![Figure 4](image)

**Figure 4.** Contacts between SARS-CoV-2 spike residues and key ACE2 amino acids identified during ACE2 mutant library screening. (A) ACE2 His34 contacts spike Leu455 and Gln493. (B) ACE2 Gln42 contacts spike Gly446. (C) ACE2 Leu79 contacts spike Phe486. ACE2 residues in green or blue (contact residues). Spike residues in red or magenta (contact residues). Figures generated from Protein Data Bank structure 6m0j (human ACE2) using Pymol.
It is reasonable to posit that Leu to Ile substitution decreases the free energy of the hydrophobic interaction between the Phe486 aromatic ring and the cognate interacting ACE2 amino acid sidechain. The imidazole group sidechain of Human ACE2 residue His34 is in direct contact with the sidechains of spike RBD residues Leu455 and Gln493; given the substantial level of primary sequence conservation across mammalian ACE2s [9,13] it is plausible that contacts between ACE2 residue 34 and one or more spike RBD sidechains exist in the context of many or all of these orthologs. This may explain why high affinity ACE2 clones identified from the cat, dog, and pig libraries carried substitutions at position 34.

Discussion
In this work we performed directed evolution on four mammalian ACE2 orthologs to identify mutations that enhance binding to the SARS-CoV-2 spike protein. The identified clones revealed numerous and varied mechanisms to increase spike binding, highlighting the latent potential of SARS-CoV-2 to evolve a broad host range. We focused further analysis on ACE2 positions 42 and 79 because they are highly conserved across mammalian ACE2 homologs and mutations at these sites can enhance spike binding. We found the mutation Leu79Ile enhanced spike binding in 3/3 mammalian ACE2's tested and mutation Gln42Leu enhanced spike binding in 5/5 ACE2s tested.

Our finding that ACE2 positions 34, 42 and 79, all of which reside within ACE2's N-terminal helices, can play important roles in the ACE2-spike RBD binding interaction across multiple mammalian orthologs is in accord with prior studies of human ACE2. Procko and colleagues [14] observed that Gln42Leu and Leu79Ile mutations, as well as substitutions at His34, increased human ACE2's binding affinity toward the spike RBD. Additionally, Wells et al. [15] identified mutations at residues His34 (His34Ala, His34Ser, and His34Val) and Leu79 (Leu79Pro) that increased human ACE2 spike RBD binding affinity.

The observed impact of Gln42Leu and Leu79Ile mutations on spike RBD binding interaction for multiple ACE2 orthologs may be leveraged in the context of crystal structure-guided computational prediction of SARS-CoV-2 spike RBD mutations that could give rise to new virus strains possessing increased propensity for cross-species transmission. Such predictive efforts can find a foundation in prior respective in silico studies aimed at elucidating how animal ACE2 amino acid sequence impacts SARS-CoV-2 spike binding [16] and identifying human ACE2 residues [17] that increase the strength of the ACE2-spike interaction. Additionally, our discovery of the conserved effects of Glu42Leu and Leu79Ile ACE2 mutations could be put to use in cell culture studies focused on resolving the ACE2 and spike RBD amino acid sequence determinants.
of SARS-CoV-2 infectivity for both humans and animals; Farzan and co-workers [18] have previously quantified the in vitro infection susceptibilities of respective human cell lines transfected with more than a dozen mammalian ACE2 orthologs upon challenge with both SARS-CoV-2 and related coronaviruses.

The findings presented in this work, as well as other related computational and experimental pursuits, will contribute to our understanding of how ACE2 and spike RBD amino acid sequences influence SARS-CoV-2 transmission among humans and other mammals. This heightened understanding could play an important role in developing novel vaccines for both humans and animals and contribute to global food security by facilitating the establishment of effective practices for ensuring the health of farmed animal populations.

**Experimental Procedures**

**ACE2 library generation and screening**

Residues 18-615 of the human (UniProt Q9BYF1), cat (Q56H28), dog (E2RR65) and pig (K7GLM4) ACE2 genes were synthesized as yeast codon-optimized gBlocks (Integrated DNA Technologies, Coralville, IA) and ligated into the NheI and MluI sites of yeast display vector VLRB.2D-aga2 (provided by Dane Wittrup, MIT); this vector fuses the aga2 protein to the C-terminus of ACE2 (Supporting Figure 1). ACE2 genes contained His to Asn mutations at positions 376 and 380 to abolish zinc binding and ACE2 proteolytic activity. The GeneMorph II Kit (Agilent Technologies, Santa Clara, CA) was employed to generate ACE2 random mutant libraries using the wild type ACE2 display plasmid as template and respective forward and reverse primers CDspLt (5’-GTCTTGTTGGCTATCTTCGCTG-3’) and CDspRt (5’-GTCGTTGACAAAGAGTACG-3’). Error prone PCR products from the GeneMorph random mutagenesis reactions were digested NheI to MluI and ligated into VLRB.2D-aga2. Ligation products were concentrated using the Zymoclean Clean & Concentrator 5 kit (Zymo Research, Orange, CA) and electroporated into 10G Supreme E. coli (Lucigen, Middleton, WI). Transformants were pooled and cultured in LB media containing 100ug/mL carbenecillin overnight at 30°C and plasmids subsequently harvested using the Qiagen (Valencia, CA) Spin Miniprep kit.

Yeast display *Saccharomyces cerevisiae* strain EBY100 was made competent using the Sigma-Aldrich (St. Louis, MO) yeast transformation kit. Transformants were pooled and cultured in low-pH Sabouraud Dextrose Casamino Acid media (SDCAA, per liter - 20 g dextrose, 6.7 grams yeast nitrogen base (VWR Scientific, Radnor, PA), 5 g Casamino Acids (VWR), Citrate buffer (pH 4.5) - 10.4 g sodium citrate / 7.4 g citric acid monohydrate) at 30°C and 250 rpm for two days. For induction of ACE2 mutant library display a 5 mL Sabouraud Galactose Casamino Acid (SGCAA,
per liter - Phosphate buffer (pH 7.4) - 8.6 g NaH2PO4·H2O / 5.4 g Na2HPO4, 20 g galactose, 6.7 g yeast nitrogen base, 5 g Casamino Acids) culture was started at an optical density, as measured at 600 nm, of 0.5 and shaken overnight at 250 rpm and 20°C.

After overnight induction approximately $3 \times 10^6$ yeast cells were harvested by centrifugation, washed once in pH 7.4 Phosphate Buffered Saline (PBS) containing 0.2% (w/v) bovine serum albumin (BSA) and incubated overnight at 4°C on a tube rotator at 18 rpm in 1.2 mL of PBS/0.2% BSA containing 3 μg/mL anti-myc IgY (Aves Labs, Tigard, OR) and the following concentrations of His$_6$-tagged SARS-CoV-2 spike RBD (Sino Biological, Chesterbrook, PA): 1.5nM (human), 5nM (cat), 5nM (pig) and 50nM (dog). These spike concentrations were used in all three rounds of sorting. Following overnight incubation yeast were washed once in PBS/0.2% BSA and rotated at 18 rpm in same buffer containing 5 μg/mL mouse anti-His6 IgG (BioLegend, San Diego, CA) that had been conjugated with Alexa647 using N-hydroxysuccinimidyld ester chemistry (Molecular Probes, Eugene, OR) and 2 μg/mL Alexa488-conjugated goat anti-chicken IgG (Jackson ImmunoResearch, West Grove, PA) for one hour at 4°C. Yeast cells were subsequently washed and resuspended in ice cold PBS for sorting on a FACS Aria III (Becton Dickinson, Franklin Lakes, NJ) located in the University of Wisconsin-Madison Carbone Cancer Center Flow Cytometry Laboratory. Sorting gates were set such that ACE2 mutant library members at or above approximately the 97th percentile with respect to binding to spike RBD were isolated.

Yeast cells isolated during sorting were cultured overnight in low pH SDCAA media at 30°C with shaking at 250 rpm and the following morning $1 \times 10^8$ yeast cells were harvested and induced as described above for a second round of incubation with spike RBD and sorting; this process was repeated after the second sort to perform a third and final round of sorting. Yeast enriched in round three sorts were plated on synthetic dropout (SD) -Trp (MP Biomedicals, Irvine, CA) agar plates and grown at 30°C for two days.

*Flow cytometric analysis and sequencing of ACE2 library clones enriched during FACS*

Along with wild type ACE2 yeast, five single colonies for each animal ACE2 library sort were picked into 4 mL of low pH SDCAA and grown overnight at 30°C with shaking at 250 rpm. Cultures were subsequently induced in 5 mL of SGCAA overnight at 20°C with shaking at 250 rpm; induction culture starting OD was 0.5. After overnight induction of ACE2 surface display yeast cells for each ACE2 variant to be analyzed were harvested by centrifugation and washed once as described above. $2 \times 10^5$ yeast cells were tumbled overnight at 4°C in 500 μL of PBS/0.2% BSA containing 3 μg/mL anti-myc IgY and various concentrations of His6-tagged spike RBD as denoted in Figure 2. Secondary labeling, yeast cell washing, and resuspension in ice cold PBS.
were performed as above prior to carrying out analysis using a Fortessa (Becton Dickinson) flow cytometer in the University of Wisconsin-Madison Biochemical Sciences Building.

ACE2 library clones with greater than wild type binding affinity were repicked and recultured from the post-sort agar plates and yeast display plasmids rescued using the ZymoPrep Yeast Plasmid Miniprep II kit (Zymo Research). ACE2 genes were amplified using primers CDspLt and CDspRt, PCR reactions cleaned up using the Qiaquick PCR purification kit, and PCR products submitted for ACE2 gene sequencing with the CDspLt and CDspRt primers.

**Flow cytometric analysis of ACE2 Gln42Leu mutants**

For the four above mammalian ACE2s, as well as the greater halcyon bat (UniProt A0A0N7IQX6) ACE2, Gln42Leu mutant genes were constructed by overlap extension PCR using codon optimized wild type ACE2 gBlocks as template, digested with NheI and MluI, and ligated into VLRB.2D-aga2 as described above. Plasmids for Gln42Leu mutant and wild type ACE2s were transformed into EBY100 yeast made competent using the Zymo Research Frozen EZ Yeast Transformation II kit with transformants plated onto SD -Trp agar plates and allowed to grow at 30°C. Using the methods described above, single colonies were cultured, induced, labeled with various concentrations of spike RBD as noted in Figure 3, and analyzed using the Fortessa flow cytometer. Values in Figure 3 are mean fluorescence units (MFU) for gated, myc-positive ACE2-displaying yeast populations minus MFU for gated, myc-negative nondisplaying yeast.

**References**


**Abbreviations & Nomenclature**

ACE2 - Angiotensin-Converting Enzyme II  
MFU - Mean Fluorescence Units  
SD - Synthetic Dropout  
SDCAA - Sabouraud Dextrose Casamino Acid Media  
SGCAA - Sabouraud Galactose Casamino Acid Media

**Data availability**

All data is contained within the manuscript.

**Author contributions**

P.H. and P.A.R conceived the project. P.H. performed the experiments. P.H. and P.A.R analyzed the data. P.H. and P.A.R. wrote the manuscript.

**Funding and additional information**

This work was supported by the US National Institutes of Health (5R35GM119854). "The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

**Conflict of interest**

The authors declare that they have no conflicts of interest with the contents of this article.